全文获取类型
收费全文 | 201322篇 |
免费 | 34228篇 |
国内免费 | 2644篇 |
专业分类
耳鼻咽喉 | 5641篇 |
儿科学 | 7193篇 |
妇产科学 | 3709篇 |
基础医学 | 10871篇 |
口腔科学 | 2241篇 |
临床医学 | 31410篇 |
内科学 | 58504篇 |
皮肤病学 | 8481篇 |
神经病学 | 20255篇 |
特种医学 | 7393篇 |
外科学 | 44844篇 |
综合类 | 524篇 |
现状与发展 | 73篇 |
一般理论 | 43篇 |
预防医学 | 11849篇 |
眼科学 | 4154篇 |
药学 | 4887篇 |
中国医学 | 142篇 |
肿瘤学 | 15980篇 |
出版年
2024年 | 759篇 |
2023年 | 5359篇 |
2022年 | 2566篇 |
2021年 | 5374篇 |
2020年 | 7267篇 |
2019年 | 3859篇 |
2018年 | 9177篇 |
2017年 | 8769篇 |
2016年 | 9983篇 |
2015年 | 10135篇 |
2014年 | 17717篇 |
2013年 | 18467篇 |
2012年 | 9843篇 |
2011年 | 9823篇 |
2010年 | 12565篇 |
2009年 | 16103篇 |
2008年 | 9052篇 |
2007年 | 7296篇 |
2006年 | 9436篇 |
2005年 | 6445篇 |
2004年 | 5521篇 |
2003年 | 4223篇 |
2002年 | 4087篇 |
2001年 | 4000篇 |
2000年 | 3162篇 |
1999年 | 3429篇 |
1998年 | 3947篇 |
1997年 | 3722篇 |
1996年 | 3536篇 |
1995年 | 3374篇 |
1994年 | 2107篇 |
1993年 | 1695篇 |
1992年 | 1463篇 |
1991年 | 1483篇 |
1990年 | 1115篇 |
1989年 | 1247篇 |
1988年 | 1080篇 |
1987年 | 910篇 |
1986年 | 939篇 |
1985年 | 770篇 |
1984年 | 629篇 |
1983年 | 585篇 |
1982年 | 590篇 |
1981年 | 462篇 |
1980年 | 420篇 |
1979年 | 338篇 |
1978年 | 359篇 |
1977年 | 431篇 |
1975年 | 297篇 |
1972年 | 315篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
42.
43.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
44.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
45.
Grazyna Bednarek-Tupikowska Alicja Filus Justyna Kuliczkowska-P?aksej Krzysztof Tupikowski Anna Bohdanowicz-Pawlak Andrzej Milewicz 《Gynecological endocrinology》2006,22(4):207-212
AIM: The aim of the present study was to investigate the influence of endogenous estradiol and estrogen and estrogen-progestin therapies on concentration in pre- and postmenopausal women. MATERIALS AND METHODS: The study groups consisted of 26 women with surgical menopause (mean+/-standard deviation (SD): age 51.8+/-2.6 years, body mass index (BMI) 26.45+/-4.56 kg/m(2)), 54 with natural menopause (mean+/-SD: age 50.5+/-3.0 years, BMI 25.75+/-4.09 kg/m(2)) and 40 premenopausal controls (mean+/-SD: age 48.3+/-2.3 years, BMI 26.23+/-4.12 kg/m(2)). The group with surgical menopause received estradiol transdermally (50 microg/day) and those with natural menopause received additionally medroxyprogesterone acetate (5 mg/day) for the last 12 days of the cycle. Before and after 4 months of therapy, body weight, waist and hip circumferences and blood pressure were measured, and BMI and waist-to-hip ratio (WHR) were calculated. Serum leptin, follicle-stimulating hormone (FSH), estradiol (E(2)), testosterone, prolactin and dehydroepiandrosterone sulfate (DHEAS) were measured prior to and after treatment. RESULTS: Leptin concentrations did not differ statistically among the groups. No correlations between leptin and E(2), FSH, prolactin, testosterone and DHEAS concentrations were found in any of the groups before and after treatment. Leptin level correlated positively with body mass, BMI and hip and waist circumferences in all groups. There were no correlations between leptin and WHR in the pre- and postmenopausal groups. In the premenopausal group and in some postmenopausal groups, serum leptin level correlated with blood pressure. CONCLUSIONS: Endogenous E(2) and androgens in premenopausal women and estrogen and estrogen-progestin therapies in postmenopausal subjects do not influence serum leptin concentrations. Leptin level is related to body mass and BMI, but not to sex hormone status. The distribution of adipose tissue and the type of obesity (android or gynoid) have no influence on serum leptin concentration. The correlation between serum leptin level and blood pressure requires further investigation. 相似文献
46.
47.
INTRODUCTION: The clinical presentation of morphea varies from localized plaques to generalized eruptions. Its cause remains unknown and medical treatments have often proved unsatisfactory. Studies have previously shown that improvement of hypertrophic scars and fibrotic skin can be achieved with the use of a 585 nm pulsed dye laser (PDL). METHODS: A case of plaque-type morphea was treated with 585 nm pulsed dye laser irradiation at an average fluence of 5.0 J/cm2 at bimonthly time intervals. RESULTS: Marked clinical improvement as evidenced by improved pliability and skin coloration was seen after 4 successive PDL treatments. No side effects or complications were encountered. CONCLUSION: Pulsed dye laser therapy is a viable treatment option for morphea. The mechanism of its effect in this condition remains unknown. 相似文献
48.
Angiotensin Converting Enzyme Inhibitors: Animal Experiments Suggest a New Pharmacological Treatment for Alcohol Abuse in Humans 总被引:1,自引:0,他引:1
G. Spinosa MSc E. Perlanski Dipl Tech. F. H. H. Leenen MD R. B. Stewart MSc L. A. Grupp DSc 《Alcoholism, clinical and experimental research》1988,12(1):65-70
The prevalence of heavy alcohol consumption is a major problem of increasing proportions throughout the world. Although alcohol sensitizing drugs and more recently serotonin uptake inhibitors are drug interventions with some following, their long term beneficial consequences have yet to be demonstrated. In recent years, we have demonstrated that manipulating activity in the renin-angiotensin system will dramatically alter voluntary alcohol consumption in rats. Based on these findings, the present study evaluated the ability of a class of drugs known as the angiotensin converting enzyme inhibitors to reduce voluntary alcohol drinking in laboratory animals. These drugs prevent the conversion of angiotensin I to angiotensin II. They have been licensed for use in Europe and North America and are indicated in the treatment of hypertension. Our experiments showed that both captopril (Capoten, Squibb) and enalapril (Vasotec, Merck Sharpe & Dohme) can reduce alcohol drinking in both normotensive and hypertensive animals regardless of whether the pattern of intake is in a bout or of a less exaggerated nature. Furthermore, this change in alcohol intake can occur without concomitant changes in blood pressure, plasma renin activity, overall fluid balance, or the distribution and metabolism of alcohol. Taken together these findings suggest that the angiotensin converting enzyme inhibitors should be evaluated in a clinical setting for they may prove to be a useful new treatment or treatment adjunct for alcohol abuse in humans. 相似文献
49.
50.